NetworkNewsBreaks – Scinai Immunotherapeutics Lt

NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Expands CDMO Operations with New U.S. Subsidiary

Scinai Immunotherapeutics (NASDAQ: SCNI) has established a U.S.-based subsidiary, Scinai Bioservices Inc., to enhance its Contract Development and Manufacturing Organization (CDMO) operations and address the growing demand for early-stage biologics development in the U.S. Operating from a cGMP-compliant facility in Jerusalem, Israel, Scinai Bioservices has supported nine biotech companies since its 2024 launch and recently signed its first U.S. customer, Serpin Pharma. The new subsidiary will provide boutique CDMO services tailored to early-stage biotech startups, leveraging U.S. grant funding opportunities while addressing concerns related to the BIOSECURE Act. Scinai anticipates significant growth in its CDMO revenues and reputation in the coming years.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer